Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Proc Natl Acad Sci U S A ; 112(20): 6431-6, 2015 May 19.
Article in English | MEDLINE | ID: mdl-25941374

ABSTRACT

The molecular mechanisms underlying pathogen emergence in humans is a critical but poorly understood area of microbiologic investigation. Serotype V group B Streptococcus (GBS) was first isolated from humans in 1975, and rates of invasive serotype V GBS disease significantly increased starting in the early 1990s. We found that 210 of 229 serotype V GBS strains (92%) isolated from the bloodstream of nonpregnant adults in the United States and Canada between 1992 and 2013 were multilocus sequence type (ST) 1. Elucidation of the complete genome of a 1992 ST-1 strain revealed that this strain had the highest homology with a GBS strain causing cow mastitis and that the 1992 ST-1 strain differed from serotype V strains isolated in the late 1970s by acquisition of cell surface proteins and antimicrobial resistance determinants. Whole-genome comparison of 202 invasive ST-1 strains detected significant recombination in only eight strains. The remaining 194 strains differed by an average of 97 SNPs. Phylogenetic analysis revealed a temporally dependent mode of genetic diversification consistent with the emergence in the 1990s of ST-1 GBS as major agents of human disease. Thirty-one loci were identified as being under positive selective pressure, and mutations at loci encoding polysaccharide capsule production proteins, regulators of pilus expression, and two-component gene regulatory systems were shown to affect the bacterial phenotype. These data reveal that phenotypic diversity among ST-1 GBS is mainly driven by small genetic changes rather than extensive recombination, thereby extending knowledge into how pathogens adapt to humans.


Subject(s)
Adaptation, Biological/genetics , Biological Evolution , Communicable Diseases, Emerging/epidemiology , Communicable Diseases, Emerging/microbiology , Streptococcus agalactiae/genetics , Adult , Base Sequence , Cluster Analysis , Genome, Bacterial/genetics , Humans , Likelihood Functions , Models, Genetic , Molecular Sequence Data , Ontario/epidemiology , Phylogeny , Polymorphism, Single Nucleotide/genetics , Sequence Analysis, DNA , Serogroup , Species Specificity , Texas/epidemiology
2.
Pharm Stat ; 14(3): 189-97, 2015.
Article in English | MEDLINE | ID: mdl-25689055

ABSTRACT

Opsonophagocytic killing assays (OPKA) are routinely used for the quantification of bactericidal antibodies in blood serum samples. Quantification of the OPKA readout, the titer, provides the basis for the statistical analysis of vaccine clinical trials having functional immune response endpoints. Traditional OPKA titers are defined as the maximum serum dilution yielding a predefined bacterial killing threshold value, and they are estimated by fitting a dose-response model to the dilution-killing curve. This paper illustrates a novel definition of titer, the threshold-free titer, which preserves biological interpretability while not depending on any killing threshold or on a postulated shape of the dose-response curve. These titers are shown to be more precise than the traditional threshold-based titers when using simulated and experimental group B streptococcus OPKA experimental data. Also, titer linearity is shown to be not measurable when using threshold-based titers, whereas it becomes measurable using threshold-free titers. The biological interpretability and operational characteristics demonstrated here indicate that threshold-free titers are an appropriate tool for the routine analysis of OPKA data.


Subject(s)
Antibodies, Bacterial/blood , Biological Assay , Statistics as Topic , Streptococcus agalactiae/immunology , Bacterial Vaccines/therapeutic use , Biological Assay/methods , Clinical Trials as Topic , Humans , Models, Statistical
3.
Article in English | MEDLINE | ID: mdl-24100558

ABSTRACT

Streptococcus pyogenes (Group A streptococcus; GAS) is an important human pathogen against which an effective vaccine does not yet exist. The S. pyogenes protein SpyCEP (S. pyogenes cell-envelope proteinase) is a surface-exposed subtilisin-like serine protease of 1647 amino acids. In addition to its auto-protease activity, SpyCEP is capable of cleaving interleukin 8 and related chemokines, contributing to GAS immune-evasion strategies. SpyCEP is immunogenic and confers protection in animal models of GAS infections. In order to structurally characterize this promising vaccine candidate, several SpyCEP protein-expression constructs were designed, cloned, produced in Escherichia coli, purified by affinity chromatography and subjected to crystallization trials. Crystals of a selenomethionyl form of a near-full-length SpyCEP ectodomain were obtained. The crystals diffracted X-rays to 3.3 Šresolution and belonged to space group C2, with unit-cell parameters a=139.2, b=120.4, c=104.3 Å, ß=111°.


Subject(s)
Antigens, Bacterial/chemistry , Antigens, Bacterial/isolation & purification , Peptide Hydrolases/chemistry , Peptide Hydrolases/isolation & purification , Streptococcal Vaccines/immunology , Streptococcus pyogenes/immunology , X-Ray Diffraction , Cloning, Molecular , Crystallization , Crystallography, X-Ray , Humans , Peptide Hydrolases/immunology , Protein Structure, Tertiary , Selenomethionine/chemistry
4.
Proc Natl Acad Sci U S A ; 102(39): 13950-5, 2005 Sep 27.
Article in English | MEDLINE | ID: mdl-16172379

ABSTRACT

The development of efficient and inexpensive genome sequencing methods has revolutionized the study of human bacterial pathogens and improved vaccine design. Unfortunately, the sequence of a single genome does not reflect how genetic variability drives pathogenesis within a bacterial species and also limits genome-wide screens for vaccine candidates or for antimicrobial targets. We have generated the genomic sequence of six strains representing the five major disease-causing serotypes of Streptococcus agalactiae, the main cause of neonatal infection in humans. Analysis of these genomes and those available in databases showed that the S. agalactiae species can be described by a pan-genome consisting of a core genome shared by all isolates, accounting for approximately 80% of any single genome, plus a dispensable genome consisting of partially shared and strain-specific genes. Mathematical extrapolation of the data suggests that the gene reservoir available for inclusion in the S. agalactiae pan-genome is vast and that unique genes will continue to be identified even after sequencing hundreds of genomes.


Subject(s)
Genome, Bacterial , Streptococcus agalactiae/classification , Streptococcus agalactiae/genetics , Amino Acid Sequence , Bacterial Capsules/genetics , Base Sequence , Gene Expression , Genes, Bacterial , Genetic Variation , Molecular Sequence Data , Phylogeny , Sequence Alignment , Sequence Analysis, DNA , Streptococcus agalactiae/pathogenicity , Virulence/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...